BIEL PATH TO COPPERThe PR released a few days ago did not move the PPS because it did not provide any new information, other than confirming the PO and that manufacturing has commenced. The following would get us to COPPER, which would instantly strengthen BIEL and Electrome's ability to secure funding by improving valuation, leverage, credibility and investor confidence.
Below is the 4‑PR Momentum Engine.
PR #1 — The “Numbers Hit the Table” PR
Timing: Immediately
Purpose: Convert the vague “initial purchase order” into a real catalyst.
Headline:
Electrome Issues $X Initial Purchase Order to BioElectronics as Commercial Launch Buildout Accelerates
Key Elements:
Actual PO dollar value
Unit count
Confirmation that this is the first of multiple scheduled orders
Manufacturing capacity expansion
Confirmation of Electrome’s launch timeline (e.g., “Q3 rollout”)
A quote from Electrome confirming reorder expectations
Why this moves PPS:
It transforms “manufacturing underway” into quantified demand, which the current PR does not provide.
PR #2 — The “Channel Expansion” PR
Timing: 5–10 days after PR #1
Purpose: Show that Electrome isn’t just marketing — they’re placing BIEL into real distribution channels.
Headline:
Electrome Secures Initial Retail & Digital Distribution Channels for ActiPatch Rollout
Key Elements:
Confirm 1–3 named channels (even small ones)
Confirm Electrome’s ecommerce platform launch date
Confirm integration into Electrome’s AI-native consumer funnel
Mention early demand indicators (waitlist signups, pre‑launch interest, etc.)
Why this moves PPS:
It shows traction, not just “preparing” or “building” — which is all the current PR says .
PR #3 — The “Clinical / Regulatory Leverage” PR
Timing: 7–14 days after PR #2
Purpose: Add legitimacy and widen the addressable market.
Headline:
BioElectronics Expands Clinical & Regulatory Positioning to Support Electrome’s National Rollout
Key Elements:
New clinical data summary
New application areas (e.g., post‑operative, chronic pain, sports recovery)
Any regulatory updates (EU, Canada, VA, etc.)
A statement tying this directly to Electrome’s marketing strategy
Why this moves PPS:
It reframes BIEL as a validated medical technology, not just a consumer gadget.
The current PR mentions FDA clearance but adds no new clinical or regulatory substance.
PR #4 — The “Launch Activation” PR
Timing: 10–20 days after PR #3
Purpose: Deliver the big catalyst — the one that creates the breakout.
Headline:
Electrome Launches National AI-Driven Consumer Campaign for ActiPatch With Multi‑Channel Rollout
Key Elements:
Official launch date
Marketing budget range
Influencer / partnership confirmations
Early sales data (even small numbers move PPS)
Confirmation of reorder pipeline
Quotes from both CEOs about scaling
Why this moves PPS:
This is the activation event — the moment the market sees:
real demand
real marketing
real revenue
real scale
The current PR only says Electrome is “preparing” and “building” these systems, not launching them .
Optional PR #5 — The “Momentum Amplifier”
Timing: 3–7 days after PR #4
Purpose: Sustain the breakout.
Headline:
BioElectronics Reports Surge in Consumer Demand Following Electrome Launch Campaign
Key Elements:
Early sales velocity
Conversion rates
Reorder rate
Customer satisfaction metrics
Testimonials
Electrome’s next-phase marketing plans
Why this moves PPS:
It confirms the launch wasn’t a one‑day event — it’s a trend.
Why This Sequence Works
Because it fixes the exact weaknesses in the PR released a few days ago:
No numbers
No scale
No timelines
No channels
No launch date
No revenue visibility
No clinical expansion
No traction metrics
Each PR in the sequence adds one missing piece until the market has a complete, investable story.
Below is the 4‑PR Momentum Engine.
PR #1 — The “Numbers Hit the Table” PR
Timing: Immediately
Purpose: Convert the vague “initial purchase order” into a real catalyst.
Headline:
Electrome Issues $X Initial Purchase Order to BioElectronics as Commercial Launch Buildout Accelerates
Key Elements:
Actual PO dollar value
Unit count
Confirmation that this is the first of multiple scheduled orders
Manufacturing capacity expansion
Confirmation of Electrome’s launch timeline (e.g., “Q3 rollout”)
A quote from Electrome confirming reorder expectations
Why this moves PPS:
It transforms “manufacturing underway” into quantified demand, which the current PR does not provide.
PR #2 — The “Channel Expansion” PR
Timing: 5–10 days after PR #1
Purpose: Show that Electrome isn’t just marketing — they’re placing BIEL into real distribution channels.
Headline:
Electrome Secures Initial Retail & Digital Distribution Channels for ActiPatch Rollout
Key Elements:
Confirm 1–3 named channels (even small ones)
Confirm Electrome’s ecommerce platform launch date
Confirm integration into Electrome’s AI-native consumer funnel
Mention early demand indicators (waitlist signups, pre‑launch interest, etc.)
Why this moves PPS:
It shows traction, not just “preparing” or “building” — which is all the current PR says .
PR #3 — The “Clinical / Regulatory Leverage” PR
Timing: 7–14 days after PR #2
Purpose: Add legitimacy and widen the addressable market.
Headline:
BioElectronics Expands Clinical & Regulatory Positioning to Support Electrome’s National Rollout
Key Elements:
New clinical data summary
New application areas (e.g., post‑operative, chronic pain, sports recovery)
Any regulatory updates (EU, Canada, VA, etc.)
A statement tying this directly to Electrome’s marketing strategy
Why this moves PPS:
It reframes BIEL as a validated medical technology, not just a consumer gadget.
The current PR mentions FDA clearance but adds no new clinical or regulatory substance.
PR #4 — The “Launch Activation” PR
Timing: 10–20 days after PR #3
Purpose: Deliver the big catalyst — the one that creates the breakout.
Headline:
Electrome Launches National AI-Driven Consumer Campaign for ActiPatch With Multi‑Channel Rollout
Key Elements:
Official launch date
Marketing budget range
Influencer / partnership confirmations
Early sales data (even small numbers move PPS)
Confirmation of reorder pipeline
Quotes from both CEOs about scaling
Why this moves PPS:
This is the activation event — the moment the market sees:
real demand
real marketing
real revenue
real scale
The current PR only says Electrome is “preparing” and “building” these systems, not launching them .
Optional PR #5 — The “Momentum Amplifier”
Timing: 3–7 days after PR #4
Purpose: Sustain the breakout.
Headline:
BioElectronics Reports Surge in Consumer Demand Following Electrome Launch Campaign
Key Elements:
Early sales velocity
Conversion rates
Reorder rate
Customer satisfaction metrics
Testimonials
Electrome’s next-phase marketing plans
Why this moves PPS:
It confirms the launch wasn’t a one‑day event — it’s a trend.
Why This Sequence Works
Because it fixes the exact weaknesses in the PR released a few days ago:
No numbers
No scale
No timelines
No channels
No launch date
No revenue visibility
No clinical expansion
No traction metrics
Each PR in the sequence adds one missing piece until the market has a complete, investable story.
